Upload
Featured Recent Articles Topics Login Upload

Search Results for 'peg rbv'

peg rbv published presentations and documents on DocSlides.

PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
NS5A and polymerase inhibitors
NS5A and polymerase inhibitors
by LoveBug
Mark Sulkowski, MD. Professor of Medicine. Johns H...
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection
by karlyn-bohler
John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
Hepatitis C Drug Pipeline
Hepatitis C Drug Pipeline
by cheryl-pisano
HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...
Current strategies for the management of treatment naïve a
Current strategies for the management of treatment naïve a
by min-jolicoeur
Mark S. Sulkowski, MD. Medical Director, Viral He...
HIV and HCV Update for the Pharmacist – June 2014
HIV and HCV Update for the Pharmacist – June 2014
by marina-yarberry
John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...
David Fletcher, MD
David Fletcher, MD
by tatiana-dople
Department of Medicine. University of Toronto. Co...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Placebo + PR
Placebo + PR
by aaron
W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...
Boceprevir with PEG + RBV in Genotype 1
Boceprevir with PEG + RBV in Genotype 1
by caroline
SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. ...
Practical management of PI therapy
Practical management of PI therapy
by TropicalParadise
in Hepatitis C . Paris . Februari. 2012. Ola . We...
Global Hepatitis C Guidelines 2014: recommendations for a public health approach
Global Hepatitis C Guidelines 2014: recommendations for a public health approach
by olivia-moreira
Gottfried . Hirnschall. Background . HCV infectio...
Sofosbuvir + Peginterferon + Ribavirin in Genotype 2
Sofosbuvir + Peginterferon + Ribavirin in Genotype 2
by debby-jeon
. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...
Simeprevir in
Simeprevir in
by ellena-manuel
Genotype . 1 . (. Viral . Relapsers. ). PROMISE ....
Management of HCV in Co-Infected Patients
Management of HCV in Co-Infected Patients
by danika-pritchard
Marie-Louise Vachon, MD, . MSc. Division of . Inf...